Summary: Apollo Health has unveiled the BrainScan Alzheimer’s disease test through Neurocode, which uses three blood tests to detect Alzheimer’s pathology, offering a less invasive and more accessible alternative to traditional methods.
Key Takeaways:
- Innovative Testing Method: The BrainScan test includes the high-sensitivity p-tau217 test and other neurological biomarkers, eliminating the need for spinal taps and costly PET scans.
- Early Detection: Neurocode’s BrainScan can detect biomarker changes years before dementia symptoms appear, enabling earlier treatment and potentially better outcomes.
- Clinical Validation: The test has undergone comprehensive clinical validation, demonstrating its accuracy and reliability, and is designed to be used alongside clinical evaluations for a complete diagnosis.
Apollo Health, a provider of innovative health solutions for cognition, unveiled the BrainScan Alzheimer’s disease test through Neurocode, a clinical laboratory that offers diagnostic tests and biomarkers.
It is comprised of three blood tests that scan for signs of Alzheimer’s disease pathology, replacing the need for painful spinal taps and expensive and inaccessible amyloid and tau PET scans to detect Alzheimer’s pathology, the company says
BrainScan Alzheimer’s Test
BrainScan features the high-sensitivity p-tau217 test * along with additional neurological biomarkers.
“Just as cancer early detection methods have saved countless lives, the new, highly sensitive BrainScan test from Neurocode will help to make dementia a much less common condition—and that is the Holy Grail of neurological treatment,” says Dale Bredesen, MD, CSO, Apollo Health.
Unlike standard Alzheimer’s disease tests, which do not turn positive until significant symptoms have occurred, Neurocode’s high-sensitivity p-tau 217 detects biomarker changes years before symptoms of dementia occur, providing an opportunity for early treatment and better outcomes, the company says.
For more information on the accuracy of these tests, please go to: https://jamanetwork.com/journals/jamaneurology/fullarticle/2813751
“We are thrilled that Apollo Health has chosen Neurocode Laboratory and recognizes the diligence that went into this test that makes us stand apart from other offerings in the market,” says Hans Frykman, MD, CSO, Neurocod. “Neurocode’s comprehensive clinical validation, conducted in partnership with leading memory clinics worldwide, has demonstrated the accuracy and reliability of our testing.”
*Note: These tests alone do not provide a definitive diagnosis and should be interpreted by a qualified practitioner in conjunction with clinical signs and symptoms.
